Market Place
Sourcing Support
NIMML Institute Presents LANCL Receptor Research at Immunology2024
10 Apr 2024 //
BUSINESSWIRE
ImmunoMet Therapeutics Announces First Patient Dosed in a Ph 1b Trial of IM156
17 Nov 2022 //
BUSINESSWIRE
Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
26 Jul 2021 //
BUSINESSWIRE
ImmunoMet Therapeutics Granted Fast Track Designation by USFDA for IM156
03 May 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.